These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28502030)

  • 1. Co-occurrence of type I CALR and two MPL mutations in patient with primary myelofibrosis.
    Tashkandi H; Moore EM; Tomlinson B; Goebel T; Sadri N
    Ann Hematol; 2017 Aug; 96(8):1417-1418. PubMed ID: 28502030
    [No Abstract]   [Full Text] [Related]  

  • 2. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High resolution melting analysis: a rapid and accurate method to detect CALR mutations.
    Bilbao-Sieyro C; Santana G; Moreno M; Torres L; Santana-Lopez G; Rodriguez-Medina C; Perera M; Bellosillo B; de la Iglesia S; Molero T; Gomez-Casares MT
    PLoS One; 2014; 9(7):e103511. PubMed ID: 25068507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
    Finazzi MC; Carobbio A; Cervantes F; Isola IM; Vannucchi AM; Guglielmelli P; Rambaldi A; Finazzi G; Barosi G; Barbui T
    Leukemia; 2015 May; 29(5):1209-10. PubMed ID: 25482134
    [No Abstract]   [Full Text] [Related]  

  • 5. Essential thrombocythaemia with mutation in
    Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
    J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients.
    Zaidi U; Sufaida G; Rashid M; Kaleem B; Maqsood S; Mukry SN; Khan RZA; Munzir S; Borhany M; Shamsi TS
    BMC Cancer; 2020 Mar; 20(1):205. PubMed ID: 32164591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.
    Asp J; Andréasson B; Hansson U; Wasslavik C; Abelsson J; Johansson P; Palmqvist L
    Haematologica; 2016 Apr; 101(4):e129-32. PubMed ID: 26768689
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
    Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
    Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
    Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
    J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
    Rumi E; Cazzola M
    Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calreticulin mutation profile in Indian patients with primary myelofibrosis.
    Sazawal S; Singh N; Mahapatra M; Saxena R
    Hematology; 2015 Dec; 20(10):567-70. PubMed ID: 25959795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential Thrombocythaemia.
    Pich A; Riera L; Francia di Celle P; Beggiato E; Benevolo G; Godio L
    Acta Haematol; 2018; 140(4):234-239. PubMed ID: 30404086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients.
    ElNahass YH; Mahmoud HK; Mattar MM; Fahmy OA; Samra MA; Abdelfattah RM; ElRefaey FA; Fahmy HM; Fathy GM; Abdulgawad A; AbdelKader M; Elleithy HN; Gamil M; Talaat M; Nader HA; ElMetnawy WH
    Leuk Lymphoma; 2018 Apr; 59(4):844-854. PubMed ID: 28828906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
    Marty C; Pecquet C; Nivarthi H; El-Khoury M; Chachoua I; Tulliez M; Villeval JL; Raslova H; Kralovics R; Constantinescu SN; Plo I; Vainchenker W
    Blood; 2016 Mar; 127(10):1317-24. PubMed ID: 26608331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.
    Shammo JM; Stein BL
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):552-560. PubMed ID: 27913528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CALR mutation characterization in myeloproliferative neoplasms.
    Bilbao-Sieyro C; Florido Y; Gómez-Casares MT
    Oncotarget; 2016 Aug; 7(33):52614-52617. PubMed ID: 27384487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction.
    Daly S; Conneally E; Langabeer SE
    Acta Haematol; 2009; 121(4):221-2. PubMed ID: 19521067
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.